阿托伐他汀对单纯收缩期高血压患者血管内皮功能的影响  

Effects of atorvastatin administration on vascular endothelial function in patients of isolated systolic hypertension

作　　者：王骄[1] 梅霞[1] 

机构地区：[1]重庆市中山医院心内科,400013

出　　处：《重庆医学》2010年第13期1695-1697,共3页Chongqing medicine

摘　　要：目的探讨阿托伐他汀对单纯收缩期高血压患者血管内皮功能的影响。方法入选合并高脂血症的单纯收缩期高血压(ISH)患者60例,随机分为阿托伐他汀10 mg组(A组)和20 mg组(B组),另入选不合并高脂血症的对照ISH患者(C组)30例,分别于治疗12周前、后测量血压、血脂、NO、ET-1和FMD。结果治疗前A组和B组血脂、FMD、NO和ET-1等方面差异无统计学意义,但与C组比较差异有统计学意义。治疗12周后,3组LDL-C和TG均显著降低;NO和FMD水平均显著升高;ET-1水平显著降低(P<0.05)。单因素相关分析A组和B组肱动脉FMD、NO和ET-1的改善程度与患者血TC、LDL-C的基础值和降低值均不相关(P>0.05),FMD的改善程度与患者血ET-1和NO改善水平密切相关(P<0.05)。结论阿托伐他汀治疗ISH患者,其改善血管内皮功能的作用独立于其降脂作用,并呈剂量依赖性。Objective To investigate effects of atorvastatin administration on vascular endothelial function in patients of isolated systolic hypertension（ISH） with hyperlipidemia or without. Methods Sixty patients with ISH and hyperlipidemia were randomly divided into the atorvastatin 10mg group （Group A） and the 20mg group （Group 13） ,and the other 30 ISH patients without hyper- lipidemia were served as control. Blood pressure,LDL C,TC,ET-1 ,nitric oxide （NO） and FMD level were measured before and 12 weeks after the treatment. Results LDL-C,TC,FMD,NO and ET1 had no significant difference between the two groups Group A and B before treatment,but compared with Group C they were significantly different. After 12 weeks,LDL-C and TG were signifi- cantly reduced in all three groups; NO and FMD were significantly increased;And ET-1 levels were significantly lower （P〈0.05）. Univariate analysis suggested that the improvement of FMD, NO and ET-1 level were not correlated with the baseline of TC,LDL- C level and the decrease （P〉0.05） ,but the improvement of FMD had a close relation with the improvement of the serum ET-1 and NO level （P〈0.05）. Conclusion Atorvastatin obvorsly improves vascular endothelial function of patients with ISH complicated with hyperlipidemia or without,and is independent of their lipid-lowering effect and in dose-dependent manner.

关 键 词：高血压 他汀 内皮功能 

分 类 号：R544.1[医药卫生—心血管疾病] R972.6[医药卫生—内科学]